Drug Profile
ABP 102
Alternative Names: ABP-102Latest Information Update: 23 Sep 2022
Price :
$50
*
At a glance
- Originator Abiogen Pharma
- Class Monoclonal antibodies; Peptide hydrolases; Recombinant fusion proteins
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Sep 2022 Discontinued - Phase-I for Alzheimer's disease in Europe (Parenteral)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Europe (Parenteral, Injection)
- 19 Jul 2010 Phase-I clinical trials in Alzheimer's disease in Europe (Parenteral)